ProCE Banner Activity

HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

Slideset Download
Comprehensive slideset featuring data on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Released: February 18, 2022

Expiration: February 17, 2023

Share

Faculty

Lilian Abbo

Lilian Abbo, MD, MBA, FIDSA

Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Miami, Florida

Keith S. Kaye

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Jason M. Pogue

Jason M. Pogue, PharmD

Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Lilian Abbo, MD, MBA, FIDSA

Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Miami, Florida

Lilian Abbo, MD, FIDSA, has disclosed that she has received consulting fees from Ferring.

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Keith S. Kaye, MD, MPH, has disclosed that he has received consulting fees from Actavis, Allecra, Bayer, Carb-X, Cipla, Clarametyx, Contrafect, Cubist, Entasis, Integrated Operations, Melinta, Merck, Nabriva, NS Nanotech, Pratek, QPex, Shionogi, SPERO, Utility Therapeutics, VenatoRX, and Xellia.

Jason M. Pogue, PharmD

Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan

Jason M. Pogue, MD, has disclosed that he has received consulting fees from Entasis, GlaxoSmithKline, Merck, Qpex, Shionogi, Spero, and Utility.